Artiva Biotherapeutics: Wedbush cuts to neutral from outperform, cuts target price to $4 from $40
ARTV•Wedbush cut its rating on Artiva Biotherapeutics to neutral from outperform and lowered its target price to $4 from $40.
Related News
Hilton Worldwide: Susquehanna raises target price to $360 from $345
HLT•
Farmers National Banc Q3 interest income rises on acquisition boost
FMNB•
Oppenheimer cuts Wave Life Sciences target price to $29 from $32
WVE•
Nautilus Biotechnology target price raised to $4 from $3.5 by Roth MKM
NAUT•
California Bancorp reports third-quarter earnings, highlighting steady loan growth and strong deposit growth
BCAL•